Xeris Pharmaceuticals Announces Positive Topline Results From a Study of Its Novel Formulation of Diazepam Injection
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Business Wire
Xeris’ IM diazepam maintains higher concentration over longer time period versus standard of care CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive topline results from its Phase 1b weight-based dosing study of diazepam intramuscular (IM) injection utilizing its proprietary XeriSol™ technology.The Phase 1b, open-label, three-treatment, three-way crossover, randomized controlled study was conducted among 20 healthy volunteers to assess the bioavailability and pharmacokinetics (PK) of two different dose levels of a single, intramuscular (IM), weight-based dose of Xeris’ novel formulation of diazepam compared to an administration of commercial diazepam rectal gel (Diastat®). Secondary objectives were to assess the dose proportionality, safety, and tolerability of Xeris’ diazepam
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]Yahoo! Finance
- Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent ApplicationBusiness Wire
- Xeris Biopharma (NASDAQ:XERS) had its price target raised by analysts at Piper Sandler from $6.00 to $8.00. They now have a "neutral" rating on the stock.MarketBeat
- Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.MarketBeat
XERS
Earnings
- 11/6/25 - Miss
XERS
Sec Filings
- 12/2/25 - Form 4
- 12/1/25 - Form 8-K
- 11/17/25 - Form 4
- XERS's page on the SEC website